Alexandra Sokolova

Alexandra Sokolova, MD, discusses the importance of genetic testing in patients with prostate cancer, which patients may benefit most from genetic testing, and how cascade testing can identify additional people who are at risk for developing cancer.

Alexandra Sokolova, MD, discusses key findings from the phase 3 TALAPRO-2 trial in patients with metastatic castration-resistant prostate cancer and unanswered questions regarding the use of PARP inhibitors plus androgen receptor inhibitors in patients with biomarker-negative disease.

Alexandra Sokolova, MD,discusses the evaluation of rucaparib vs physician’s choice standard of care therapy in patients with BRCA-positive metastatic castration-resistant prostate cancer.

Alexandra Sokolova, MD, discusses the rationale for ​systematic germline testing in patients with metastatic prostate cancer.

Alexandra Sokolova, MD, discusses the challenges of germline testing in patients with metastatic prostate cancer. 

Alexandra Sokolova, MD, discusses the systematic implementation of a germline testing protocol for patients with metastatic prostate cancer.

Alexandra Sokolova, MD, discusses the rationale for systematic implementation of germline testing for patients with metastatic prostate cancer.